ESA Committee Review To Focus On Hemoglobin Target For Kidney Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory panel will also be asked to discuss management of non-responders at increased risk for cardiovascular harm.
You may also be interested in...
ODAC Calls For Additional EPO Trials To Support Continued Use In Oncology
In the absence of data on approved therapeutic target, panel advises adding warnings from signals in off-label use to label.
Aranesp, Epogen Share In CKD, ESRD Will Remain Stable Despite Hemoglobin Targets – JP Morgan
After surveying nephrologists, JP Morgan analysts predict that use of the erythropoiesis-stimulating agents in kidney disease settings will not change dramatically.
EPO Aggressive Dosing May Be Curtailed By New Black Box Warning
Labeling for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit updated March 9 to include a black box warning on risk of mortality.